Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Neoplasms benign, malignant and unspecified (incl cysts and polyps) – page 257

  • 3 898 clinical trials
  • 1 548 recruiting
  • 703 conditions
  • 31 countries

Conditions in this area

703 conditions with trials, the busiest first

Non-small cell lung cancer327Breast cancer168Plasma cell myeloma164Neoplasm158Acute myeloid leukaemia132Neoplasm malignant129Colorectal cancer metastatic105Prostate cancer101Ovarian cancer91Colorectal cancer89Hepatocellular carcinoma89Breast cancer metastatic84Non-small cell lung cancer metastatic82Malignant melanoma79Chronic lymphocytic leukaemia77Triple negative breast cancer69Squamous cell carcinoma of head and neck68Hormone receptor positive HER2 negative breast cancer62Non-small cell lung cancer stage IV57Pancreatic carcinoma57Hormone-refractory prostate cancer56Gastric cancer55Bladder cancer54Endometrial cancer53+679

Clinical trials in Neoplasms benign, malignant and unspecified (incl cysts and polyps)

3 898 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

3 898 clinical trials

B-cell lymphoma+1

Not recruiting

Study of Axi-Cel, Fludarabine Phosphate, and Cyclophosphamide for Patients with Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma Ineligible for Stem Cell Transplant

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Cyclophosphamide
  • Sponsor:LYSARC

Malignant melanoma+12

Not recruiting

Study on the Safety and Effects of ATL001 and Nivolumab for Adults with Metastatic or Recurrent Melanoma

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Atl001
  • Sponsor:Achilles Therapeutics UK Limited

Philadelphia positive acute lymphocytic leukaemia

Not recruiting

Study Comparing Ponatinib and Imatinib with Chemotherapy for Patients with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Imatinib
  • Sponsor:Takeda Development Center Americas Inc.

Non-small cell lung cancer stage IV+1

Not recruiting

Study of Relatlimab and Nivolumab with Chemotherapy for Patients with Stage IV or Recurrent Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Non-small cell lung cancer+1

Not recruiting

Study of Tiragolumab and Atezolizumab for Patients with Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Not Had Chemotherapy

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:Genentech Inc.

Neuroblastoma

Not recruiting

Study on Dinutuximab Beta and Chemotherapy for Patients with Neuroblastoma Resistant to Standard Treatment or with Relapsed Disease

Registered drugNo placebo
Countries:PolandPoland
  • Participants:0–17 years
  • Substances:Dinutuximab Beta
  • Sponsor:Uniwersytet Jagiellonski Collegium Medicum

Tuberous sclerosis complex

Not recruiting

Study on Cannabidiol as Add-on Therapy for Seizures in Patients Aged 1-65 with Tuberous Sclerosis Complex

Registered drugNo placebo
Countries:PolandPoland
  • Participants:0–17 years · 18–64 years
  • Substances:Cannabidiol
  • Sponsor:Jazz Pharmaceuticals Research UK Limited

Small cell lung cancer extensive stage

Not recruiting

Study of BMS-986012 with Chemotherapy for Patients with Extensive-Stage Small Cell Lung Cancer

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Human Igg1 Monoclonal Antibody Against Fucosyl-Gm1
  • Sponsor:Bristol Myers Squibb International Corporation

Chronic rhinosinusitis with nasal polyps+1

Not recruiting

Study on the Effect of Dupilumab for Patients with Chronic Rhinosinusitis with Nasal Polyps

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Dupilumab
  • Sponsor:Medical University Of Vienna

Myelofibrosis

Not recruiting

Study Comparing Fedratinib with Drug Combination for Myelofibrosis in Patients Previously Treated with Ruxolitinib

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Busulfan
  • Sponsor:Celgene Corp.

Endometrial cancer recurrent

Not recruiting

Study on the Safety and Effectiveness of Lurbinectedin and Dostarlimab for Patients with Advanced Endometrial Cancer After Platinum-based Chemotherapy

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Dostarlimab
  • Sponsor:Vall D Hebron Institute Of Oncology

Acute myeloid leukaemia

Not recruiting

Study on Midostaurin and Chemotherapy for Children with Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:0–17 years
  • Substances:Cytarabine
  • Sponsor:Novartis Pharma AG

Substances studied in this area

The therapies tested most often in Neoplasms benign, malignant and unspecified (incl cysts and polyps) trials.

Pembrolizumab462 clinical trialsCarboplatin340 clinical trialsCisplatin285 clinical trialsPaclitaxel263 clinical trialsFluorouracil237 clinical trialsOxaliplatin227 clinical trialsNivolumab217 clinical trialsDexamethasone169 clinical trialsBevacizumab163 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.